{"database": "lobbying", "table": "lobbying_activities", "rows": [[1737921, "7e993854-227b-47d1-9b8b-f9aa102aba33", "Q3", "TEVA PHARMACEUTICALS USA, INC.", 76695, "TEVA PHARMACEUTICALS USA INC", 2015, "third_quarter", "PHA", "Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; \"21st Century Cures\" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)", null, 990000, 0, 0, "2015-10-19T11:41:47.833000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1737921"], "units": {}, "query_ms": 1.0414689895696938, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}